Supplementary Figures 1-5, Supplementary Tables 1-3, Supplementary References from MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Year: 2023
Type: supplementary-materials
Abstract: Figure S1: Adaptor knockdowns. A) 72hr titration of BKM120 in MET-amplified NSCLC cell lines analyzed by Cell Titer Glo 72 hr. Figure S2: Distribution of tumor types for PDX models used in MET:GRB2 PLA survey. Figure S3: Immunohistochemistry in PDX models and cell line controls A) H&E and IHC for MET and phospho-MET (Tyr1234/5) from non-treated control mice. Figure S4: Intratumoral heterogeneity of MET:GRB2 Signaling complexes in LXFA2165. Red foci represent MET:GRB2 PLA signal. Green = cytokeratin, Blue = DAPI. Figure S5: Regression model of MET:GRB2 PLA to tumor volume change. Supplemental Table 1: Summary of MET TKi sensitivity, phospho-MET western and MET:GRB2 complex presence in 12 cell line panel Supplemental Table 2: Mutations and Mutational Burden* Identified in Top 20 Lung Adenocarcinoma Mutations as Defined by TCGA (2). Supplemental Table 3: METÎ"ex14 Patient Characteristics
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362402153